Clinical Trial: Study to Evaluate the Efficacy and Safety of Neoadjuvant Treatment Based on Dual Blockade With Pertuzumab and the Trastuzumab Biosimilar CT-P6 (Herzuma(R)) in Early HER2-positive Breast Cancer in Routine Clinical Practice

U.S., April 3 -- ClinicalTrials.gov registry received information related to the study (NCT06907082) titled 'Study to Evaluate the Efficacy and Safety of Neoadjuvant Treatment Based on Dual Blockade With Pertuzumab and the Trastuzumab Biosimilar CT-P6 (Herzuma(R)) in Early HER2-positive Breast Cancer in Routine Clinical Practice' on March 24.

Brief Summary: The study hypothesis is to evaluate whether the pCR rate of neoadjuvant chemotherapy and dual blockade with pertuzumab and the trastuzumab biosimilar CT-P6 (Herzuma(R)) in HER2-positive early breast cancer in PCH is similar to that reported in clinical trials.

Other aspects to be analyzed include the safety of the combination in PCH, as well as the clinical and tumor characteristics of...